Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells

MLA

Schardt, John S., et al. “Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.” Molecular Pharmaceutics, vol. 14, no. 4, Apr. 2017, pp. 1047–56. EBSCOhost, https://doi.org/10.1021/acs.molpharmaceut.6b00919.

APA

Schardt, J. S., Oubaid, J. M., Williams, S. C., Howard, J. L., Aloimonos, C. M., Bookstaver, M. L., Lamichhane, T. N., Sokic, S., Liyasova, M. S., O, N. M., Andresson, T., Hussain, A., Lipkowitz, S., & Jay, S. M. (2017). Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Molecular Pharmaceutics, 14(4), 1047–1056. https://doi.org/10.1021/acs.molpharmaceut.6b00919

Chicago

Schardt, John S., Jinan M. Oubaid, Sonya C. Williams, James L. Howard, Chloe M. Aloimonos, Michelle L. Bookstaver, Tek N. Lamichhane, et al. 2017. “Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.” Molecular Pharmaceutics 14 (4): 1047–56. doi:10.1021/acs.molpharmaceut.6b00919.